Key Highlights

  • Globe Life's $0.33 quarterly dividend trades ex-dividend October 5, 2026, with payment on October 30 to shareholders of record.
  • A $2.5 billion share repurchase authorization took effect August 15, replacing all prior authorizations, per the August 10 release.
  • Second-quarter GAAP net income was $3.65 per diluted share versus $3.05, and net operating income (non-GAAP) was $3.61.
  • The company raised its full-year 2026 earnings guidance to a range of $15.55 to $15.95 per diluted share.

Globe Life Inc. (NYSE:GL) declared a quarterly dividend of $0.33 per share, a yield of 0.80%, payable October 30 to shareholders of record on October 5, 2026. The company announced a new $2.5 billion share repurchase authorization effective August 15. Second-quarter GAAP net income was $3.65 per diluted share.

Dividend Program and Shareholder Returns

Globe Life's board declared the quarterly dividend of $0.33 per share on August 6, 2026, payable October 30 to shareholders of record on October 5. The shares trade ex-dividend on October 5.

In an August 10 release, the company announced a $2.5 billion share repurchase authorization, effective August 15, that replaces its prior authorizations. The company stated that it has returned nearly $11.5 billion to shareholders through share repurchases since 1986. In the second quarter, Globe Life repurchased 1.1 million shares for $175 million, and it stated that liquidity at the parent company is sufficient to meet additional capital needs of its insurance companies.

About the Company

Globe Life Inc. is an insurance holding company that sells life and supplemental health insurance through operating units including American Income, Liberty National, Family Heritage and United American. In the second quarter, the company reported total revenue of $1.599730 billion, compared with $1.481287 billion a year earlier, and shareholders' equity of $6.156 billion.

Premium Growth, Underwriting Income and Book Value

Globe Life reported second-quarter GAAP net income of $3.65 per diluted share, compared with $3.05 a year earlier. Net operating income, a non-GAAP measure, was $3.61 per diluted share, compared with $3.27. Weighted-average diluted shares were 78.909 million, compared with 82.793 million. For the first six months, GAAP net income was $558.3 million, and net operating income (non-GAAP) was $558.2 million.

Total premium revenue rose 7%. Life premium was $860.8 million, compared with $839.5 million, and health premium was $436.9 million, compared with $378.1 million, an increase of 16%. Underwriting income was $370.3 million, compared with $354.2 million, and net investment income was $293.820 million, compared with $282.169 million. Excess investment income was $38.3 million, up 10%.

Book value per share, which includes accumulated other comprehensive income, was $78.18, up 18% from the year-ago quarter. Return on equity based on GAAP net income was 18.4% for the six months, and net operating income return on equity excluding accumulated other comprehensive income, a non-GAAP measure, was 14.3%.

Agency Results and 2026 Earnings Guidance Reported by Globe Life

Globe Life reported that second-quarter American Income life premium rose 5% to $466.334 million, United American health premium rose 29% to $211.416 million, and Family Heritage health underwriting margin rose 10% to $45.087 million. The company reported that average producing agent count rose 8% at Liberty National and 7% at Family Heritage, that Liberty National life underwriting margin rose 10% to $36.652 million, and that net sales rose 6% for Liberty National life, 4% for Family Heritage health and 10% for United American health. Management raised full-year 2026 earnings guidance to a range of $15.55 to $15.95 per diluted share, an increase of $0.10 at the midpoint.

Outlook

Globe Life's $0.33 quarterly dividend is payable October 30 to shareholders of record on October 5, 2026. Earnings relative to the $15.55 to $15.95 guidance range, health premium growth, and use of the $2.5 billion share repurchase authorization are the relevant considerations.